Millennium Management LLC Acquires New Stake in TuHURA Biosciences (NASDAQ:HURA)

Millennium Management LLC bought a new stake in TuHURA Biosciences (NASDAQ:HURA) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 33,808 shares of the company’s stock, valued at approximately $138,000.

Several other institutional investors and hedge funds have also bought and sold shares of HURA. Apollon Wealth Management LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $253,000. Suncoast Equity Management bought a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $421,000. Charles Schwab Investment Management Inc. purchased a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $61,000. Accent Capital Management LLC purchased a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $29,000. Finally, Geode Capital Management LLC bought a new position in TuHURA Biosciences in the fourth quarter worth approximately $1,084,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock opened at $2.62 on Friday. The stock’s 50-day simple moving average is $3.62 and its 200-day simple moving average is $3.90. TuHURA Biosciences has a 52 week low of $1.80 and a 52 week high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of TuHURA Biosciences in a research report on Friday, May 16th.

TuHURA Biosciences Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.